Morgan Stanley Reiterates Equalweight Rating on Gilead Sciences (GILD)

Goldman Sachs Reiterates Neutral Rating on Gilead Sciences (GILD)

Goldman Sachs analyst Salveen Richter reiterated a Neutral rating and $71.00 price target on Gilead Sciences (NASDAQ: GILD).

The analyst comments "GILD reported positive topline interim Ph3 (PURPOSE 2) data where twice-yearly subcutaneous lenacapavir achieved superiority vs. background HIV incidence (bHIV) (primary endpoint) and Truvada (secondary endpoint) in cisgender men, transgender men and women, and gender non-binary... More

BMO Capital Gilead Sciences (GILD) at Outperform following latest HIV data

BMO Capital analyst Evan David Seigerman reiterated an Outperform rating and $85.00 price target on Gilead Sciences (NASDAQ: GILD).

The analyst commented: "Lenacapavir PURPOSE-2 data reaffirms potential for long-acting PrEP and expedites timelines for filing and approval. PURPOSE-2 study showed 2 HIV infections per 2,180 patients,... More

Gilead says HIV prevention injection reduced cases by 96%, sending shares higher

Investing.com -- Shares in Gilead Sciences (NASDAQ: GILD) rose in early US trading on Thursday after the pharmaceutical group announced that a Phase 3 trial of its HIV drug reduced infections of the disease.

In a statement, Gilead said that twice-yearly use of its injectable treatment, lenacapavir, led to 96% fewer infections compared to background HIV levels in patients who were not on any prevention regimen. The trial... More

Gilead's (GILD) Twice-Yearly Lenacapavir for HIV Prevention Reduced HIV Infections by 96% and Demonstrated Superiority to Daily Truvada

Gilead Sciences, Inc. (Nasdaq: GILD) today announced the results of an interim analysis from a second pivotal Phase 3 clinical trial investigating the use of the companys twice-yearly injectable HIV-1 capsid inhibitor, lenacapavir. Lenacapavir reduced HIV infections by 96% compared to background HIV incidence (bHIV). There were 2 incident cases among 2,180 participants, corresponding to 99.9% of participants not acquiring HIV infection in the lenacapavir group. Twice-yearly lenacapavir also demonstrated superiority to once-daily Truvada® (emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg; F/TDF).

The trial, PURPOSE 2... More

Piper Sandler Reiterates Overweight Rating on Gilead Sciences (GILD)

Piper Sandler analyst Joseph Catanzaro reiterated an Overweight rating and $95.00 price target on Gilead Sciences (NASDAQ: GILD).

The analyst commented, "At WCLC, GILD, AZN/Daiichi (not covered), and Jiangsu provided updates on their respective TROP2-targeting ADC programs. Most notably, GILD reported... More

Gilead Sciences (GILD) and Genesis Therapeutics Enter Strategic Collaboration to Discover and Develop Novel Therapies

-- Gilead Receives Exclusive Rights to Develop and Commercialize Products from the Collaboration --

Gilead Sciences, Inc. (Nasdaq: GILD) and Genesis Therapeutics, Inc. announced today that the companies have entered into a strategic collaboration to discover and develop novel, small molecule therapies across multiple targets.

Genesis is pioneering generative and predictive artificial intelligence (AI) technologies to help create therapeutics for challenging targets. This collaboration will deploy Genesis field-leading AI platform, GEMS (Genesis Exploration of Molecular Space), to assist in generating and... More